OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Manu Vandijck

2 Projects | 1 Researchers | $1,588,415 Invested

2024

Fujirebio Europe NV

Manu Vandijck

Plasma pTau217 detection with the LUMIPULSE G platform as indicator for Alzheimer’s Disease

  • Funding Amount: $725,922
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2021

Fujirebio Europe NV

Manu Vandijck

Easy and early plasma pTau181 detection with the LUMIPULSE G platform as indicator of Alzheimer's disease.

  • Funding Amount: $862,493
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Tau
  • Status: Closed